Comparisons

Wegovy vs. Zepbound: Comparing the Two Leading Weight Loss Injections

GLP-1 Companion · 8 min read

If you are exploring prescription weight loss options, two names come up more than any others: Wegovy (semaglutide) and Zepbound (tirzepatide). Both are FDA-approved injectable medications for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Despite that shared indication, they differ in mechanism, clinical outcomes, dosing, and cost.

How Each Medication Works

Wegovy is a GLP-1 receptor agonist. It mimics the natural hormone GLP-1, which slows gastric emptying, increases satiety signals in the brain, and helps regulate blood sugar. Zepbound is a dual GIP/GLP-1 receptor agonist, meaning it activates two incretin pathways simultaneously. The addition of GIP activity may amplify the appetite-suppressing and metabolic effects beyond what GLP-1 alone achieves.

Clinical Trial Results: Weight Loss

Head-to-head data and cross-trial comparisons consistently show that tirzepatide (the active ingredient in Zepbound) produces greater average weight loss than semaglutide (the active ingredient in Wegovy).

• Wegovy (STEP trials): Participants lost an average of 15-17% of their body weight over 68 weeks at the maximum 2.4 mg dose.
• Zepbound (SURMOUNT trials): Participants lost an average of 18-22.5% of their body weight over 72 weeks at the maximum 15 mg dose.
• The SURMOUNT-5 head-to-head trial confirmed tirzepatide produced statistically greater weight loss than semaglutide at maximum doses.

Dosing Schedules Compared

Both medications are administered as once-weekly subcutaneous injections, but their titration schedules differ significantly.

Wegovy Titration

1. Weeks 1-4: 0.25 mg weekly
2. Weeks 5-8: 0.5 mg weekly
3. Weeks 9-12: 1 mg weekly
4. Weeks 13-16: 1.7 mg weekly
5. Week 17 onward: 2.4 mg weekly (maintenance dose)

Zepbound Titration

1. Weeks 1-4: 2.5 mg weekly
2. Weeks 5-8: 5 mg weekly
3. Weeks 9-12: 7.5 mg (optional intermediate step)
4. Weeks 13-16: 10 mg weekly
5. Week 17 onward: up to 15 mg weekly (maintenance dose)

Both schedules take about four months to reach the target maintenance dose. Gradual titration is essential to minimize gastrointestinal side effects.

Side Effects

Because both medications act on similar pathways, their side effect profiles overlap considerably. The most common adverse events are gastrointestinal.

• Nausea (reported in roughly 30-45% of patients on either drug)
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain
• Injection-site reactions

Most GI side effects are dose-dependent and tend to improve over the first few weeks at each new dose level. Serious but rare side effects for both include pancreatitis, gallbladder problems, and potential thyroid C-cell tumor risk (boxed warning).

Cost and Insurance Coverage

Without insurance, both medications are expensive. List prices have ranged from roughly $1,000 to $1,300 per month, though manufacturer savings programs and pharmacy discounts can reduce out-of-pocket costs.

• Wegovy is manufactured by Novo Nordisk and has been on the market since June 2021, giving it a longer track record of insurance negotiation.
• Zepbound is manufactured by Eli Lilly and received FDA approval for weight management in November 2023.
• Insurance coverage varies widely by plan. Some insurers cover one but not the other, and many still exclude weight loss medications entirely.
• Both manufacturers offer savings cards for commercially insured patients that can reduce costs to $0-$25 per month for eligible individuals.

Who Is Each Medication Best For?

There is no single "better" drug for everyone. Several factors guide the choice between Wegovy and Zepbound.

• Patients who also have type 2 diabetes may benefit from tirzepatide's stronger glucose-lowering effect (Mounjaro, the diabetes-branded version, is FDA-approved for T2D).
• Patients already on semaglutide for diabetes (Ozempic) can transition to Wegovy more seamlessly.
• Insurance formulary placement often dictates the practical choice.
• Individual tolerability matters: if one medication causes intolerable side effects, switching to the other is reasonable.

The Bottom Line

Wegovy and Zepbound are both powerful tools for chronic weight management. Zepbound tends to produce slightly greater average weight loss in clinical trials due to its dual-agonist mechanism, while Wegovy has a longer market presence and broader insurance coverage history. The best medication for you depends on your health profile, insurance, tolerability, and your prescriber's clinical judgment.

Neither Wegovy nor Zepbound is a standalone solution. Both work best when combined with a reduced-calorie diet, increased physical activity, and behavioral changes.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.